NASDAQ
DXR
Last Price
US $10.29
KEY FIGURES
MKT CAP
$50.5M
EPS
TTM
$1.81
PEG
TTM
0.00x
P/E
TTM
5.52x
P/S
TTM
100.32x
YIELD
0.00%
GROWTH
Revenue Y/Y
-
(FY vs FY)
EBITDA Y/Y
Cash Flow (DCF)
Fair Value
Market $10.29
—
Default assumptions
EBITDA Multiple
Fair Value
Market $10.29
23.81%
Default assumptions
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Daxor Corporation cash flow to debt ratio of -539.66% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Daxor Corporation's free cash flow has decreased -2.45K% from $25.69K last year to $-604.42K, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Daxor Corporation's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Daxor Corporation's debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Daxor Corporation has a net debt to EBITDA ratio of 0.01x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Daxor Corporation earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
Daxor Corporation's profit margin has increased (24.16K%) in the last year from 25.17% to 6.11K%, signaling increasing performance
Financial risk - Short term assets vs short term liabilities.
Daxor Corporation's short-term liabilities of $122.59K exceed its short-term assets of $0.00, signaling financial risk
Increasing performance - ROA.
Daxor Corporation's return on assets of 19.93% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Daxor Corporation's return on equity of 22.50%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Daxor Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
Daxor Corporation had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Decreasing performance - Free cash flow.
Daxor Corporation has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Daxor Corporation has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Daxor Corporation's yearly earnings has increased 1.61K% since last year from $536.33K to $9.17M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
Daxor Corporation's yearly revenue has decreased -76.37% since last year from $2.13M to $503.42K, signaling decreasing performance
Increasing performance - ROIC.
ROIC 20.21% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Decreasing performance - 3-year revenue CAGR.
Daxor Corporation has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Daxor Corporation had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Daxor Corporation had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Daxor Corporation has insufficient data to evaluate this check.
Undervalued - Earnings yield.
Daxor Corporation has an earnings yield of 18.09%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Undervalued - EBITDA valuation.
Daxor Corporation is undervalued relative to its fair value price of 12.74 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Daxor Corporation has an EV/EBITDA ratio of 5.30x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Daxor Corporation has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
Daxor Corporation has a price-to-book ratio of 1.11x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Daxor Corporation has a price-to-sales ratio of 336.27x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
22.50%
Return on equity
ROIC: 20.21%
Valuation History
5.5X
Price to Earnings
EV/EBITDA: 5.3X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
32.28%
(FY vs FY)
EARNINGS FV (GRAHAM)
Fair Value
Market $10.29
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.